TNDM - Tandem Diabetes Care Inc Stock Price, Fair Value and News

47.30+0.37 (+0.79%)Market Closed

Market Summary

47.30+0.37

Market Closed

0.79%

TNDM Alerts

Big jump in Earnings (Y/Y)

Losses in recent quarter

TNDM Stock Price

View Fullscreen

TNDM RSI Chart

TNDM Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-21.6

Price/Sales (Trailing)

3.97

EV/EBITDA

-29.28

Price/Free Cashflow

-69.57

TNDM Price/Sales (Trailing)

TNDM Profitability

EBT Margin

-17.69%

Return on Equity

-58.2%

Return on Assets

-15.03%

Free Cashflow Yield

-1.44%

TNDM Fundamentals

TNDM Revenue

Revenue (TTM)

770.0M

Rev. Growth (Yr)

13.16%

Rev. Growth (Qtr)

-2.6%

TNDM Earnings

Earnings (TTM)

-141.5M

Earnings Growth (Yr)

65.52%

Earnings Growth (Qtr)

-42.37%

Breaking Down TNDM Revenue

Last 7 days

6.6%

Last 30 days

49.0%

Last 90 days

93.7%

Trailing 12 Months

59.7%

How does TNDM drawdown profile look like?

TNDM Financial Health

Current Ratio

3.81

Debt/Equity

1.43

Debt/Cashflow

-0.06

TNDM Investor Care

Buy Backs (1Y)

0.05%

Diluted EPS (TTM)

-2.17

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	770.0M	0	0	0
2023	794.7M	790.3M	771.4M	747.7M
2022	737.7M	765.8M	790.7M	801.2M
2021	541.9M	604.8M	660.9M	702.8M
2020	394.2M	410.2M	439.2M	498.8M
2019	222.6M	281.7M	330.1M	362.3M
2018	115.9M	128.7M	148.0M	183.9M
2017	83.2M	81.5M	96.2M	107.6M
2016	80.6M	87.9M	84.5M	84.2M
2015	54.0M	59.4M	61.6M	72.8M
2014	31.6M	36.3M	42.1M	49.7M
2013	9.1M	15.7M	22.4M	29.0M
2012	0	0	0	2.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Tandem Diabetes Care Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	carpenter rick	sold (taxes)	-4,149	28.62	-145	chief technology officer
Mar 15, 2024	carpenter rick	acquired	-	-	405	chief technology officer
Feb 27, 2024	gasser elizabeth anne	sold (taxes)	-3,554	27.34	-130	evp, chief strategy officer
Feb 27, 2024	morrison susan	sold (taxes)	-3,089	27.34	-113	evp & chief admin. officer
Feb 27, 2024	leal james	acquired	-	-	309	chief manufacturing officer
Feb 27, 2024	leal james	sold (taxes)	-3,417	27.34	-125	chief manufacturing officer
Feb 27, 2024	morrison susan	acquired	-	-	407	evp & chief admin. officer
Feb 27, 2024	gasser elizabeth anne	acquired	-	-	372	evp, chief strategy officer
Feb 27, 2024	vosseller leigh	sold (taxes)	-3,882	27.34	-142	evp & chief financial officer
Feb 27, 2024	sheridan john f	acquired	-	-	819	president & ceo

Which funds bought or sold TNDM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	61.57	5,269,150	10,909,800	-%
May 16, 2024	Beacon Capital Management, LLC	sold off	-100	-4,196	-	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.06	277,350	2,308,340	-%
May 16, 2024	COMERICA BANK	reduced	-9.67	82,715	1,099,210	-%
May 15, 2024	BROWN CAPITAL MANAGEMENT LLC	added	29.94	12,071,000	33,801,200	0.60%
May 15, 2024	Point72 (DIFC) Ltd	new	-	975,590	975,590	0.03%
May 15, 2024	Integral Health Asset Management, LLC	new	-	7,967,250	7,967,250	0.74%
May 15, 2024	Walleye Capital LLC	new	-	177,794	177,794	-%
May 15, 2024	First Light Asset Management, LLC	added	31.88	6,166,490	16,822,500	1.29%
May 15, 2024	Quarry LP	added	3,587	659,799	675,092	0.13%

Are Funds Buying or Selling TNDM?

Are funds buying TNDM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TNDM

No. of Funds

Unveiling Tandem Diabetes Care Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	eminence capital, lp	7.9%	5,170,451	SC 13G
Feb 13, 2024	vanguard group inc	10.77%	7,021,906	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	capital world investors	10.0%	6,536,778	SC 13G/A
Jan 23, 2024	blackrock inc.	14.2%	9,259,187	SC 13G/A
Jun 12, 2023	fmr llc	-	0	SC 13G/A
May 10, 2023	capital world investors	10.0%	6,473,192	SC 13G/A
Apr 10, 2023	vanguard group inc	10.92%	7,047,477	SC 13G/A
Apr 06, 2023	blackrock inc.	14.3%	9,206,880	SC 13G/A
Feb 13, 2023	capital world investors	7.7%	4,978,524	SC 13G/A

Recent SEC filings of Tandem Diabetes Care Inc

View All Filings

Date Filed	Form Type	Document
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 17, 2024	4	Insider Trading
May 16, 2024	8-K	Current Report
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report

Peers (Alternatives to Tandem Diabetes Care Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	181.0B	40.3B	-1.75%	-4.07%	32.18	4.49	-2.84%	-3.08%
BDX	68.3B	19.7B	1.78%	-6.05%	51.24	3.46	4.82%	-17.56%
ALGN	20.4B	3.9B	-9.57%	-7.50%	44.2	5.22	5.72%	46.72%
BAX	18.0B	14.9B	-10.73%	-18.01%	6.79	1.21	2.98%	207.68%
MID-CAP
ATR	9.8B	3.5B	6.68%	24.08%	31.27	2.76	6.16%	35.06%
HSIC	9.6B	12.5B	6.31%	-2.51%	24.63	0.77	-0.61%	-18.83%
BIO	8.4B	2.6B	1.13%	-22.65%	-26.02	3.22	-6.25%	-68.62%
XRAY	5.9B	3.9B	-6.79%	-30.12%	-62.84	1.49	0.23%	91.03%
AXNX	3.4B	387.1M	0.52%	31.17%	-216.3	8.9	30.82%	65.57%
PDCO	2.3B	6.6B	0.19%	-5.50%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	5.94%	-10.00%	-1.91	0.41	7.94%	-1661.78%
ANIK	376.6M	169.3M	-1.13%	-2.23%	-4.9	2.23	7.49%	-244.90%
ANGO	241.9M	324.0M	-4.58%	-37.15%	-1.26	0.75	-3.19%	-337.41%
APYX	56.1M	50.5M	22.73%	-73.49%	-2.46	1.11	14.25%	-10.06%
AEMD	1.0M	3.7M	-71.83%	-87.10%	-0.09	0.28	5.77%	8.23%

Tandem Diabetes Care Inc News

Latest updates

Tandem Diabetes Care Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In null)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-2.6%	191,674	196,796	185,622	195,917	169,383	220,502	204,547	200,262	175,907	209,996	179,627	172,139	141,037	168,065	123,603	109,236	97,926	108,398	94,657	93,255	65,995
Gross Profit	1.5%	94,672	93,295	89,753	101,735	82,907	115,523	104,425	101,946	91,093	113,729	96,745	92,454	73,287	90,556	65,313	54,390	50,261	60,272	50,683	49,904	33,353
Operating Expenses	6.2%	136,350	128,355	121,298	140,543	210,724	133,300	151,918	114,185	106,431	100,991	89,025	87,022	76,524	71,894	66,322	66,427	63,834	58,128	56,687	51,769	44,350
S&GA Expenses	5.1%	90,106	85,751	79,328	97,610	89,814	97,692	84,104	80,614	73,271	71,499	64,923	66,523	58,563	54,518	50,228	50,440	49,717	45,561	44,649	40,565	34,961
R&D Expenses	-	-	-	-	-	-	-	-	33,571	33,160	29,492	24,102	20,499	17,961	17,376	16,094	15,987	14,117	12,568	12,038	11,204	9,389
EBITDA Margin	44.3%	-0.15*	-0.27*	-0.24*	-0.26*	-0.23*	-0.10*	-0.06*	0.01*	0.03*	0.05*	0.06*	0.04*	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	2,157	-	-	-	2,157	-	-	-	-	-	-	-	-	-	-	-
Income Taxes	342.4%	3,186	-1,314	2,232	1,146	300	-247	1,600	2,100	-1,724	329	54.00	61.00	-100	51.00	39.00	-2,100	98.00	77.00	72.00	-	-
Earnings Before Taxes	-26.1%	-39,529	-31,339	-30,700	-34,629	-123,600	-16,157	-47,300	-12,950	-16,439	11,123	5,848	4,069	-5,161	17,069	-9,400	-29,182	-14,800	2,729	-2,829	-1,512	-
EBT Margin	40.0%	-0.18*	-0.29*	-0.27*	-0.28*	-0.25*	-0.12*	-0.08*	-0.02*	0.01*	0.02*	0.03*	0.01*	-	-	-	-	-	-	-	-	-
Net Income	-42.4%	-42,715	-30,002	-32,961	-35,775	-123,873	-15,852	-48,970	-15,056	-14,715	10,808	5,794	4,008	-5,044	17,000	-9,408	-27,107	-14,867	2,652	-2,901	-1,512	-22,992
Net Income Margin	38.3%	-0.18*	-0.30*	-0.27*	-0.28*	-0.26*	-0.12*	-0.09*	-0.02*	0.01*	0.02*	0.03*	0.01*	-	-	-	-	-	-	-	-	-
Free Cashflow	-0.3%	-12,453	-12,415	-5,345	-13,700	-27,154	193	10,233	-5,216	11,157	13,889	31,049	27,080	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-1.2%	941	953	940	947	954	1,053	1,048	1,037	1,015	905	850	795	754	716	673	616	343	326	293	255	215
Current Assets	-1.7%	735	748	758	764	758	850	834	835	818	812	755	698	662	637	592	540	281	276	247	213	186
Cash Equivalents	0.2%	59.00	59.00	80.00	131	128	173	124	115	94.00	71.00	112	99.00	121	95.00	129	222	74.00	51.00	46.00	38.00	40.00
Inventory	-2.6%	154	158	143	148	132	111	105	88.00	80.00	69.00	66.00	67.00	67.00	64.00	71.00	62.00	60.00	49.00	41.00	27.00	23.00
Net PPE	1.3%	78.00	77.00	76.00	74.00	75.00	69.00	73.00	59.00	50.00	50.00	50.00	49.00	50.00	50.00	49.00	44.00	38.00	33.00	28.00	23.00	17.00
Liabilities	9.2%	698	639	626	617	615	613	626	587	578	472	461	449	441	350	346	349	136	131	126	110	94.00
Current Liabilities	-1.2%	193	195	187	175	171	165	174	139	132	132	120	109	103	104	106	114	100	99.00	100	84.00	77.00
Long Term Debt	21.9%	347	285	285	284	284	283	283	282	282	281	281	281	280	203	199	195	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	285	285	284	284	283	283	282	282	281	281	281	280	203	199	195	-	-	-	-	-
Shareholder's Equity	-22.5%	243	314	314	329	339	440	422	450	437	433	390	346	313	366	327	268	207	195	167	145	121
Retained Earnings	-4.5%	-994	-951	-921	-888	-853	-729	-713	-664	-649	-634	-645	-651	-655	-659	-676	-666	-639	-624	-627	-624	-623
Additional Paid-In Capital	-2.0%	1,238	1,264	1,238	1,219	1,192	1,171	1,140	1,118	1,090	1,068	1,035	997	968	1,025	1,003	934	847	820	794	770	744
Accumulated Depreciation	-100.0%	-	53.00	-	-	-	56.00	-	-	-	49.00	-	-	-	39.00	-	-	-	30.00	-	-	-
Shares Outstanding	-1.5%	65.00	66.00	65.00	65.00	65.00	65.00	64.00	64.00	64.00	63.00	63.00	63.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,600	-	-	-	3,800	-	-	-	-	-	-	-	5,400	-	-	-	3,600	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-10.8%	-8.00	-7.22	0.00	-6.32	-18.33	6.00	24.00	7.00	14.00	20.00	34.00	29.00	29.00	15.00	15.00	15.00	-20.63	19.00	23.00	4.00	-4.12
Share Based Compensation	-3.1%	22.00	23.00	21.00	23.00	21.00	24.00	22.00	20.00	18.00	17.00	16.00	15.00	13.00	13.00	13.00	16.00	16.00	19.00	17.00	12.00	10.00
Cashflow From Investing	69.5%	-5.06	-16.58	-48.52	6.00	-26.33	36.00	-14.16	6.00	5.00	-76.82	-39.20	-64.76	-6.09	-59.63	-137	-131	33.00	-20.90	-22.17	-14.66	1.00
Cashflow From Financing	419.1%	14.00	3.00	-1.91	4.00	-0.54	6.00	-0.77	8.00	4.00	16.00	19.00	14.00	4.00	9.00	30.00	264	11.00	6.00	7.00	9.00	2.00
Buy Backs	-	30.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TNDM Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Sales	$ 191,674	$ 169,383
Cost of sales	97,002	86,476
Gross profit	94,672	82,907
Operating expenses:
Selling, general and administrative	90,106	89,814
Research and development	46,244	42,160
Acquired in-process research and development expenses	0	78,750
Total operating expenses	136,350	210,724
Operating loss	(41,678)	(127,817)
Other income (expense), net:
Interest income and other, net	5,314	5,865
Interest expense	(1,897)	(1,634)
Loss on extinguishment of debt	(1,268)	0
Total other income (expense), net	2,149	4,231
Loss before income taxes	(39,529)	(123,586)
Income tax expense	3,186	287
Net loss	(42,715)	(123,873)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments	(1,296)	1,749
Foreign currency translation losses	(1,008)	(25)
Comprehensive loss	$ (45,019)	$ (122,149)
Net loss per share - basic (in dollars per share)	$ (0.65)	$ (1.92)
Net loss per share - diluted (in dollars per share)	$ (0.65)	$ (1.92)
Weighted average shares used to compute basic net loss per share (in shares)	65,326	64,549
Weighted average shares used to compute diluted net loss per share (in shares)	65,326	64,549

TNDM Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 58,979	$ 58,868
Short-term investments	408,831	409,044
Accounts receivable, net	92,965	105,555
Inventories	153,893	157,937
Prepaid and other current assets	20,525	16,585
Total current assets	735,193	747,989
Property and equipment, net	77,530	76,542
Operating lease right-of-use assets	88,286	87,791
Other long-term assets	40,036	40,336
Total assets	941,045	952,658
Current liabilities:
Accounts payable	48,143	49,586
Accrued expenses	10,932	12,726
Employee-related liabilities	41,676	43,430
Operating lease liabilities	17,320	17,060
Deferred revenue	44,562	43,994
Other current liabilities	30,338	28,462
Total current liabilities	192,971	195,258
Convertible senior notes, net - long-term	347,497	285,035
Operating lease liabilities - long-term	112,732	113,572
Deferred revenue - long-term	12,299	13,331
Other long-term liabilities	32,482	31,830
Total liabilities	697,981	639,026
Commitments and contingencies (Note 13)	0	0
Stockholders’ equity:
Common stock, $0.001 par value; 200,000 shares authorized, 64,563 and 65,552 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.	65	66
Additional paid-in capital	1,238,449	1,263,997
Accumulated other comprehensive income (loss)	(935)	1,369
Accumulated deficit	(994,515)	(951,800)
Total stockholders’ equity	243,064	313,632
Total liabilities and stockholders’ equity	$ 941,045	$ 952,658

About Tandem Diabetes Care Inc

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

CEO	Mr. John F. Sheridan
WEBSITE	tandemdiabetes.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	2600

Tandem Diabetes Care Inc Frequently Asked Questions

What is the ticker symbol for Tandem Diabetes Care Inc? What does TNDM stand for in stocks?

TNDM is the stock ticker symbol of Tandem Diabetes Care Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tandem Diabetes Care Inc (TNDM)?

As of Fri May 17 2024, market cap of Tandem Diabetes Care Inc is 3.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNDM stock?

You can check TNDM's fair value in chart for subscribers.

What is the fair value of TNDM stock?

You can check TNDM's fair value in chart for subscribers. The fair value of Tandem Diabetes Care Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tandem Diabetes Care Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNDM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tandem Diabetes Care Inc a good stock to buy?

The fair value guage provides a quick view whether TNDM is over valued or under valued. Whether Tandem Diabetes Care Inc is cheap or expensive depends on the assumptions which impact Tandem Diabetes Care Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNDM.

What is Tandem Diabetes Care Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, TNDM's PE ratio (Price to Earnings) is -21.6 and Price to Sales (PS) ratio is 3.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNDM PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tandem Diabetes Care Inc's stock?

In the past 10 years, Tandem Diabetes Care Inc has provided -0.114 (multiply by 100 for percentage) rate of return.